---
pmid: '22439931'
title: 'Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease
  etiology and therapeutics.'
authors:
- Su L
- Sampaio AV
- Jones KB
- Pacheco M
- Goytain A
- Lin S
- Poulin N
- Yi L
- Rossi FM
- Kast J
- Capecchi MR
- Underhill TM
- Nielsen TO
journal: Cancer Cell
year: '2012'
full_text_available: false
pmcid: PMC3734954
doi: 10.1016/j.ccr.2012.01.010
---

# Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
**Authors:** Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO
**Journal:** Cancer Cell (2012)
**DOI:** [10.1016/j.ccr.2012.01.010](https://doi.org/10.1016/j.ccr.2012.01.010)
**PMC:** [PMC3734954](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734954/)

## Abstract

1. Cancer Cell. 2012 Mar 20;21(3):333-47. doi: 10.1016/j.ccr.2012.01.010.

Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease 
etiology and therapeutics.

Su L(1), Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, 
Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO.

Author information:
(1)Biomedical Research Centre, University of British Columbia, Vancouver, 
British Columbia V6T 1Z3, Canada.

Comment in
    Cancer Cell. 2012 Mar 20;21(3):323-4. doi: 10.1016/j.ccr.2012.02.023.

Synovial sarcoma is a translocation-associated sarcoma where the underlying 
chromosomal event generates SS18-SSX fusion transcripts. In vitro and in vivo 
studies have shown that the SS18-SSX fusion oncoprotein is both necessary and 
sufficient to support tumorigenesis; however, its mechanism of action remains 
poorly defined. We have purified a core SS18-SSX complex and discovered that 
SS18-SSX serves as a bridge between activating transcription factor 2 (ATF2) and 
transducin-like enhancer of split 1 (TLE1), resulting in repression of ATF2 
target genes. Disruption of these components by siRNA knockdown or treatment 
with HDAC inhibitors rescues target gene expression, leading to growth 
suppression and apoptosis. Together, these studies define a fundamental role for 
aberrant ATF2 transcriptional dysregulation in the etiology of synovial sarcoma.

Copyright Â© 2012 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2012.01.010
PMCID: PMC3734954
PMID: 22439931 [Indexed for MEDLINE]
